China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva
This article was originally published in The Pink Sheet Daily
Executive Summary
Health care reform in the U.S. is a good opportunity for Fosun to gain a foothold in the U.S. market, company chair says at China's first-ever BIO conference.